Juno Therapeutics, Inc. (NASDAQ:JUNO)‘s stock had its “outperform” rating restated by analysts at Leerink Swann in a research note issued to investors on Tuesday. They presently have a $34.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s price target points to a potential upside of 40.50% from the company’s current price.

JUNO has been the subject of several other research reports. FBR & Co cut their target price on Juno Therapeutics from $30.00 to $29.00 and set a “mkt perform” rating for the company in a research note on Friday, May 5th. Wedbush restated a “neutral” rating and issued a $24.00 target price on shares of Juno Therapeutics in a research note on Friday, May 5th. Zacks Investment Research downgraded Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Vetr downgraded Juno Therapeutics from a “strong-buy” rating to a “strong sell” rating and set a $22.32 target price for the company. in a research note on Wednesday, March 1st. Finally, BTIG Research downgraded Juno Therapeutics from a “neutral” rating to a “sell” rating and raised their target price for the stock from $22.60 to $23.73 in a research note on Thursday, June 8th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $31.23.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Shares of Juno Therapeutics (JUNO) traded up 0.83% during midday trading on Tuesday, hitting $24.40. 595,078 shares of the stock were exchanged. The firm’s market capitalization is $2.54 billion. The stock’s 50-day moving average price is $23.97 and its 200-day moving average price is $22.09. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $43.99.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.01. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The firm had revenue of $19.30 million during the quarter, compared to analysts’ expectations of $16 million. During the same period last year, the business posted ($0.78) EPS. The company’s revenue was up 96.9% compared to the same quarter last year. On average, analysts forecast that Juno Therapeutics will post ($2.99) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/06/20/juno-therapeutics-inc-juno-given-outperform-rating-at-leerink-swann.html.

In other Juno Therapeutics news, Director Jay T. Flatley purchased 20,000 shares of the company’s stock in a transaction dated Friday, May 26th. The stock was purchased at an average price of $24.76 per share, for a total transaction of $495,200.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 15.26% of the company’s stock.

Several hedge funds have recently modified their holdings of JUNO. Teachers Advisors LLC increased its stake in shares of Juno Therapeutics by 5.8% in the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock worth $1,428,000 after buying an additional 3,531 shares during the period. Great West Life Assurance Co. Can increased its stake in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the period. Opus Point Partners Management LLC increased its stake in shares of Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 4,560 shares during the period. Baird Financial Group Inc. increased its stake in shares of Juno Therapeutics by 25.7% in the first quarter. Baird Financial Group Inc. now owns 28,583 shares of the biopharmaceutical company’s stock worth $634,000 after buying an additional 5,839 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of Juno Therapeutics by 11.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 67,000 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 7,137 shares during the period. Hedge funds and other institutional investors own 65.34% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.